Valiant Laboratories Reports Strong Profitability Turnaround for Q2 and H1 FY25
Valiant Laboratories announced its Q2 and H1 FY25 financial results, showing a significant turnaround from losses to profits. Net income reached ₹0.17 crore for Q2 and ₹1.98 crore for H1.
Financial results, especially a significant turnaround from losses to profits, directly reflect the company's core business health and future prospects. This positive performance is likely to have a high impact on investor confidence and stock valuation.
The company has shown a substantial improvement in its financial performance, moving from a net loss in the previous year's corresponding quarter and half-year to a net profit in Q2 and H1 FY25. This indicates strong operational recovery and growth.
Valiant Laboratories Limited has published its Standalone and Consolidated Audited Financial Results for the quarter and half year ended September 30, 2025. The results were published in The Financial Express (English) and Mumbai Lakshadeep (Marathi) on November 13, 2025. The financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on November 11, 2025. * For the quarter ended September 30, 2025 (Q2 FY25): * Total Income (Net) stood at ₹46.83 crore, a significant increase from ₹23.41 crore in Q2 FY24. * The company reported a Net Profit After Tax of ₹0.17 crore, a strong turnaround from a net loss of ₹5.98 crore in Q2 FY24. * Basic Earnings Per Share (EPS) improved to ₹0.03 from ₹-1.39 in Q2 FY24. * For the half year ended September 30, 2025 (H1 FY25): * Total Income (Net) reached ₹98.51 crore, up from ₹47.07 crore in H1 FY24. * Net Profit After Tax was ₹1.98 crore, compared to a net loss of ₹4.74 crore in H1 FY24. * Basic EPS for the half year was ₹0.36, a substantial improvement from ₹-1.09 in H1 FY24.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.